Cargando…
Dinutuximab beta in the treatment of high-risk neuroblastoma: A follow-up of a case series in Bratislava
Despite therapeutic advances, high-risk neuroblastoma is still associated with a poor long-term prognosis. Immunotherapy with the anti-GD2 antibody dinutuximab beta has recently been added to the standard of care for patients with high-risk neuroblastoma in our center in Bratislava, and our initial...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797591/ https://www.ncbi.nlm.nih.gov/pubmed/35089239 http://dx.doi.org/10.1097/MD.0000000000028716 |